REFERENCES
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–1861.
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769–781.
- Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
- Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, em-tricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–260.
- Riddler SA, Haubrich R, DiRienzo G, et al. A prospec-tive, randomized, phase III trial of NRTI-, Pl-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection -ACTG 5142. Presented at: XVI International AIDS Confer-ence; August 13–18, 2006; Toronto, Canada.
- Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305–2315.
- Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretro-viral therapy in HIV-infected persons. J Gen Intern Med. 200116: 625–633.
- Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004;94:1147–1151.
- Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31 (Suppl 3):S149–S153.
- Cunningham CO, Sohler NL, Berg KM, et al. Type of sub-stance use and access to HIV-related health care. AIDS Patient Care STDs. 2006;20:399–407.
- Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral sup-pression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.
- Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gif-ford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–580.
- Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psy-chiatry. 200158: 721–728.
- Sternhell PS, Corr MJ. Psychiatric morbidity and adher-ence to antiretroviral medication in patients with HIV/AIDS. Aust N Z J Psychiatry. 2002;36:528–533.
- Pence, BW, Miller WC, Gaynes BN, Eron JJ. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:159–166.
- Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Ep-idemiology Research Study. JAMA. 2001285: 1466–1474.
- Golub ET, Astemborski JA, Hoover DR, et al. Psychologic distress and progression to AIDS in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003;32:429–434.
- Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311–1316.
- Murphy DA, Roberts KJ, Hoffman D, Molina A, Lu MC. Barriers and successful strategies to antiretroviral adher-ence among HIV-infected monolingual Spanish-speaking patients. AIDS Care. 2003;15:217–230.
- Lucas GM, Chaisson, RE, Moore RD. Highly active antiret-roviral therapy in a large urban clinic: risk factors for viro-logic failure and adverse drug reactions. Ann Intern Med. 1999:131:81–87.
- Levin TP, Klibanov OM, Axelrod P, et al. A randomized trial of educational materials, pillboxes, and mailings to im-prove adherence with antiretroviral therapy in an inner city HIV clinic. J Clin Outcomes Manage. 2006;13:217–221.